Polymer-based antibody mimetics (iBodies) as immune checkpoint blocker
Scientists from IMC, together with colleagues at IOCB, have developed polymeric anti-human PD-L1 antibody mimetics (iBodies) that specifically target human hPD-L1 and block the PD-1/PD-L1 interaction in vitro with the same efficacy as monoclonal antibodies.